TECHNOPHAGE and PHAXIAM Therapeutics Enter Strategic Collaboration on Individualized Phages Therapies Against Bacteria Responsible For ~70% of the Most Common Severe Resistant Infections
TECHNOPHAGE, a Portuguese company specializing in GMP phage development and PHAXIAM Therapeutics, a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, announce today its intent to establish a strategic...
Fostering Collaboration: Technophage Joins REVERSE 2 Investigator Meeting in Hyderabad to Advance TP-102 Development
We are delighted to share that Technophage’s Clinical Trial Director, Margarida Barreto, participated in the REVERSE 2 / TP-102_102 Investigator Meeting on 19th January 2025 in Hyderabad, India. The event was promoted and organized by our colleagues at VectorB2B...
Technophage is looking for a Phage Scientist to join the team
Technophage is currently seeking a Phage Scientist to join our Research team. The ideal candidate will hold an MSc or PhD in Biology, Biochemistry, or a related Life Sciences field, with at least three years of laboratory experience in phage biology. Proficiency in...